IN8bio shares are trading higher after the company announced updated clinical data from its Phase 1 investigator-sponsored trials of INB-100 and received FDA guidance on a registration path for INB-100.
Portfolio Pulse from Benzinga Newsdesk
IN8bio shares are trading higher following the announcement of updated clinical data from its Phase 1 trials of INB-100 and receiving FDA guidance on a registration path for INB-100.
August 12, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IN8bio shares are trading higher after the company announced positive clinical data from its Phase 1 trials of INB-100 and received FDA guidance on a registration path for INB-100.
The announcement of positive clinical data and FDA guidance is a significant milestone for IN8bio, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100